Drug Profile
TGN 1412
Alternative Names: Anti-CD28 monoclonal antibody - TeGenero; CD28-SuperMAB™; TGN-1412Latest Information Update: 19 Jun 2006
Price :
$50
*
At a glance
- Originator TeGenero
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD28 antigen stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Apr 2006 Discontinued - Phase-I for Cancer in United Kingdom (unspecified route)
- 16 Mar 2006 Suspended - Phase-I for Cancer in United Kingdom (unspecified route)
- 17 Nov 2003 Preclinical trials in Cancer in Germany (unspecified route)